EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

Platform · Services Proposed services Standards and rules named

Answers about an ingredient, from identity to a regulatory dossier

Is the material what the label says? Is it clean enough? What evidence does its market require? EUTECNIQ proposes to answer these questions for biotech, pharmaceutical, botanical, food and cosmetic companies. Services are the first revenue line: they would fund the early work and build the data and models behind EUTECNIQ’s own ingredients. The page leads with three defined packages, each ending in a decision the client can act on; the complete catalog of fourteen proposed services follows, each with its client, its deliverable, the standard it would follow and the rule that usually creates the need.

Status. EUTECNIQ is in formation. It has no laboratory, hired staff, clients, prices, turnaround times or accreditation, and it offers none of these services today. Partner work would go to qualified organizations under written agreements; none is signed.

Related: Scientific deliverables · How EUTECNIQ differs · Pharmaceutical partnerships · Commercialization and licensing

Packages Proposed

Three defined packages come first; Package B would be tested first

Each package has a fixed scope, written outputs and acceptance criteria agreed in the statement of work before work starts. Each also states what it would not establish. No prices are published; a package would be quoted after a technical review of the client’s material.

Tested first: Package B. Of the three entry packages, supplier qualification and comparability would be tested first. It answers the problem with the clearest published signal, needs the least equipment, and produces a result a client can check within weeks rather than years (the first test). An illustrative Package B report shows the format of its output.

Package A: Ingredient feasibility and delivery selection

For a brand or supplier with one botanical and one intended product format.

Scope
An identity and composition baseline by independent methods, then solubility, dispersibility and stability screening. A short list of delivery approaches, such as an emulsion, a spray-dried dispersion, encapsulation or complexation, tested in a designed experiment, with in vitro bioaccessibility where relevant.
Outputs
A feasibility report with a go, change or stop recommendation for each approach, a lead prototype, early stability data, a draft specification and a list of regulatory-category questions for the client’s counsel.
Acceptance criteria
The lead prototype meets the agreed target attributes at the agreed stability pulls, marker methods are shown fit for purpose, and every rejected approach has a documented reason.
Does not establish
Systemic bioavailability, a validated shelf life or any health effect.

Package B: Supplier qualification and comparability

Tested first

For a supplier, brand or importer adding or replacing a source.

Scope
One ingredient and up to three candidate suppliers, or an incumbent against an alternate. Specification review against 21 CFR 111.70(b), identity by HPTLC (USP <203>), microscopy and a chromatographic fingerprint, contaminant panels for the destination market at accredited partners, and lot-to-lot comparison.
Outputs
A qualification report for each supplier, a comparability statement, a recommended specification and test plan, a requalification schedule, and records that support an importer’s supplier verification.
Acceptance criteria
Comparability criteria and the number of lots fixed before testing; supplier certificate results confirmed within stated method uncertainty, the confirmation 21 CFR 111.75(a)(2)(ii) requires before a certificate can be relied on.
Does not establish
That future lots will conform, or that a regulator will accept the source.

Package C: Process optimization and technology transfer

For a client moving an extraction, drying, emulsification or blending step to scale or to another manufacturer.

Scope
A process map with a closed mass balance, critical parameters found by designed experiments and the scale-dependent parameters identified. A transfer protocol is agreed with the receiving site, which performs the confirmation runs.
Outputs
A process description and control strategy, inputs to the receiving site’s master manufacturing record (21 CFR 111.205), and a transfer report.
Acceptance criteria
Receiving-site batches meet the agreed specification for the agreed number of consecutive batches, the mass balance closes within the agreed tolerance, and deviations are investigated and documented.
Does not establish
Drug process validation. FDA’s process validation guidance does not cover dietary supplements.

Standards named: 21 CFR 111.70, 111.75, 111.205; USP <203>; FDA, Process Validation: General Principles and Practices (2011). Each package draws on lines of the complete catalog below.

Three entry packages: what each is for, what it delivers and what it does not establishSchematic · content from this page
Hub diagram. Center: proposed entry packages. A: ingredient feasibility and delivery selection. B: supplier qualification and comparability, marked tested first. C: process optimization and technology transfer. Each lists who it is for, its outputs and what it does not establish.
Content from this section: Packages A, B and C as defined below. Proposed services; nothing is operating. Drawn by EUTECNIQ. Full-size SVG
Catalog Proposed

The complete catalog: fourteen proposed services

Each line is a service EUTECNIQ would offer, alone or as part of a package above, in house or managed at a qualified partner. The written outputs are the documents described on Scientific deliverables; engagement terms, IP and royalties are on Commercialization and licensing.

Proposed services with client types, deliverables, standards and regulatory drivers
ServiceTypical clientDeliverableStandard followedTypical regulatory driver
Botanical identity and authenticationSupplement brand; ingredient supplier; pharmaceutical companyIdentity report with orthogonal methods and reference materialUSP <203> HPTLC; macroscopy and microscopy; LC-MS fingerprint; DNA where DNA survives processing21 CFR 111.75(a)(1)(i) identity test for every dietary ingredient
Elemental contaminantsAll client typesResults for lead, cadmium, arsenic and mercury against the client's specificationUSP <2232> for finished supplements; USP <232> and ICH Q3D for drug products21 CFR 111.70 specifications; drug-product limits
Residual solventsExtract makers; pharmaceutical companySolvent results by classICH Q3C(R9)Drug-product limits; customer specification for extracts
Pesticides, mycotoxins, pyrrolizidine alkaloidsIngredient supplier; importer; tea and food companyResidue and toxin results against the market's limitsUSP <561> pesticide limits; Regulation (EU) 2023/915EU maximum levels; customer and import specifications
MicrobiologyAll client typesCounts and absence tests against acceptance criteriaUSP <2021>, <2022> and <2023>21 CFR 111.70 specifications
Method development and validationPharmaceutical company; biotech; ingredient supplierValidated method package ready to transferICH Q14 and Q2(R2)21 CFR 111.75(h)(1) scientifically valid methods; drug submissions
Stability programsSupplement brand; ingredient supplier; food companyProtocol, pulls, trend analysis and a supported dateICH Q1A(R2) conditions as good practiceSupport for an expiration or retest date the client chooses to print
Extraction, purification and standardization developmentIngredient supplier; biotech; pharmaceutical companyProcess development report with mass balanceClient specification; development records under the quality systemMaterial that must stay comparable from lot to lot
Formulation and bioavailability developmentSupplement brand; food and beverage company; cosmetic companyPrototype, stability data and a delivery-technology dossierClient specification; published methods for the dosage formLabel claims and the product's regulatory category
Non-targeted chemical profilingBiotech; pharmaceutical company; ingredient supplierProfile comparison between lots, sources or processes, labeled as exploratoryMethod-specific; reported with its identification confidenceComparability and adulteration questions
Supplier qualification, audits and FSVP supportSupplement brand; importer; food companySupplier qualification package and audit report21 CFR 111.75(a)(2); 21 CFR Part 1, Subpart LReliance on a supplier's certificate; FSVP for importers
NDIN and GRAS dossier preparationIngredient supplier; supplement brand; food companyNotification draft organized as FDA's guidance recommends, for counsel's reviewFDA NDI final guidance (October 2026); 21 CFR Part 170 Subpart E21 CFR 190.6; GRAS conclusions for food use
GLP and clinical study design and managementIngredient supplier; supplement brand; biotechStudy design, partner selection, monitoring and an integrated report21 CFR Part 58 and OECD test guidelines at partner GLP laboratories; 21 CFR 50 and 56 and ICH E6(R3) at partner CROsSafety evidence for a notification; evidence for a claim
International market access and technology transferIngredient supplier; supplement brand; pharmaceutical companyMarket-access assessment; transfer dossier for the receiving siteThe destination's rules; the receiving site's quality systemForeign product classification; 21 CFR 111 or 117 at the receiving site

eCFR, 21 CFR 111.70, 111.75, 190.6, Parts 1 (Subpart L), 50, 56, 58 and 170, current to October 2026; USP-NF general chapters <203>, <232>, <561>, <2021>–<2023>, <2232>; ICH Q1A(R2), Q2(R2), Q3C(R9), Q3D(R2), Q14, E6(R3); Regulation (EU) 2023/915.

The fourteen proposed services, grouped by the question they answerSchematic · content from this page
Hub diagram. Center: fourteen proposed services. Testing: identity, elemental contaminants, residual solvents, pesticides and mycotoxins and pyrrolizidine alkaloids, microbiology. Development: method development and validation, stability, extraction and purification, formulation and bioavailability, non-targeted profiling. Supply and regulatory: supplier qualification and FSVP, NDIN and GRAS dossiers, GLP and clinical study management, international market access and transfer.
Content from the catalog table in this section; the number in each badge counts its services. Drawn by EUTECNIQ. Full-size SVG
Clients Proposed

Who would buy which service

Drug developers need characterized material and methods before regulated studies. Brands and suppliers need identity, specifications and dossiers. Food and cosmetic companies need contaminant data and formulation work. The matrix is EUTECNIQ's planning assumption, not a survey.

Six client types, ten service families: where each would most likely startProposal
Proposed focus: which of ten service families each of six client types would most likely need; filled = main reason to engage, ring = occasional need, dash = not expected. A planning assumption, not market data.IdentityContam­inantsMethods,stabilityDevelop­mentNon-targetedprofilingSupplier,FSVPNDIN,GRASGLP andclinical atpartnersMarketaccessTechtransferBiotech companyBiotech company · Identity: main reason to engageBiotech company · Contaminants: occasional needBiotech company · Methods and stability: main reason to engageBiotech company · Development: main reason to engageBiotech company · Non-targeted profiling: main reason to engageBiotech company · Supplier and FSVP: occasional needBiotech company · GLP and clinical studies at partners: main reason to engageBiotech company · Technology transfer: main reason to engagePharmaceutical companyPharmaceutical company · Identity: main reason to engagePharmaceutical company · Contaminants: main reason to engagePharmaceutical company · Methods and stability: main reason to engagePharmaceutical company · Development: main reason to engagePharmaceutical company · Non-targeted profiling: main reason to engagePharmaceutical company · Supplier and FSVP: main reason to engagePharmaceutical company · GLP and clinical studies at partners: main reason to engagePharmaceutical company · International market access: occasional needPharmaceutical company · Technology transfer: main reason to engageBotanical or supplement brandBotanical or supplement brand · Identity: main reason to engageBotanical or supplement brand · Contaminants: main reason to engageBotanical or supplement brand · Methods and stability: occasional needBotanical or supplement brand · Development: main reason to engageBotanical or supplement brand · Non-targeted profiling: occasional needBotanical or supplement brand · Supplier and FSVP: main reason to engageBotanical or supplement brand · NDIN and GRAS dossiers: main reason to engageBotanical or supplement brand · GLP and clinical studies at partners: main reason to engageBotanical or supplement brand · International market access: main reason to engageBotanical or supplement brand · Technology transfer: occasional needIngredient supplier or importerIngredient supplier or importer · Identity: main reason to engageIngredient supplier or importer · Contaminants: main reason to engageIngredient supplier or importer · Methods and stability: main reason to engageIngredient supplier or importer · Development: main reason to engageIngredient supplier or importer · Non-targeted profiling: occasional needIngredient supplier or importer · Supplier and FSVP: main reason to engageIngredient supplier or importer · NDIN and GRAS dossiers: main reason to engageIngredient supplier or importer · GLP and clinical studies at partners: occasional needIngredient supplier or importer · International market access: main reason to engageIngredient supplier or importer · Technology transfer: main reason to engageFood and beverage companyFood and beverage company · Identity: occasional needFood and beverage company · Contaminants: main reason to engageFood and beverage company · Methods and stability: occasional needFood and beverage company · Development: main reason to engageFood and beverage company · Supplier and FSVP: main reason to engageFood and beverage company · NDIN and GRAS dossiers: main reason to engageFood and beverage company · GLP and clinical studies at partners: occasional needFood and beverage company · International market access: occasional needFood and beverage company · Technology transfer: occasional needCosmetic companyCosmetic company · Identity: occasional needCosmetic company · Contaminants: main reason to engageCosmetic company · Methods and stability: occasional needCosmetic company · Development: main reason to engageCosmetic company · Supplier and FSVP: occasional needCosmetic company · GLP and clinical studies at partners: occasional needCosmetic company · International market access: occasional needCosmetic company · Technology transfer: occasional needMain reason to engageMain reason to engageOccasional needOccasional needNot expectedProposed focus, not market dataProposed focus by client type: main and occasional service needsBiotech companymainIdentity; Methods and stability; Development;Non-targeted profiling; GLP and clinical studies atpartners; Technology transferoccasionalContaminants; Supplier and FSVPPharmaceutical companymainIdentity; Contaminants; Methods and stability;Development; Non-targeted profiling; Supplier andFSVP; GLP and clinical studies at partners;Technology transferoccasionalInternational market accessBotanical or supplement brandmainIdentity; Contaminants; Development; Supplier andFSVP; NDIN and GRAS dossiers; GLP and clinicalstudies at partners; International market accessoccasionalMethods and stability; Non-targeted profiling;Technology transferIngredient supplier or importermainIdentity; Contaminants; Methods and stability;Development; Supplier and FSVP; NDIN and GRASdossiers; International market access; TechnologytransferoccasionalNon-targeted profiling; GLP and clinical studies atpartnersFood and beverage companymainContaminants; Development; Supplier and FSVP;NDIN and GRAS dossiersoccasionalIdentity; Methods and stability; GLP and clinicalstudies at partners; International market access;Technology transferCosmetic companymainContaminants; DevelopmentoccasionalIdentity; Methods and stability; Supplier and FSVP;GLP and clinical studies at partners; Internationalmarket access; Technology transferFilled: main reason to engage. Ring: occasional need.Proposed focus, not market data.
Planning assumption. Pharmaceutical work would stop where GLP, GCP and drug cGMP begin; see Pharmaceutical partnerships. Cosmetic safety substantiation under MoCRA: Cosmetics and MoCRA.EUTECNIQ management proposal.
Text version of the client matrix
  • Biotech company: identity, methods, development, non-targeted profiling, studies at partners and technology transfer; contaminants and supplier work occasionally.
  • Pharmaceutical company: identity, contaminants, methods, development, profiling, supplier qualification, studies at partners and transfer; market access occasionally.
  • Botanical or supplement brand: identity, contaminants, development, supplier and FSVP work, dossiers, studies and market access; methods, profiling and transfer occasionally.
  • Ingredient supplier or importer: identity, contaminants, methods, development, supplier work, dossiers, market access and transfer; profiling and studies occasionally.
  • Food and beverage company: contaminants, development, supplier work and GRAS dossiers; identity, methods, studies, access and transfer occasionally.
  • Cosmetic company: contaminants and formulation development; identity, methods, supplier work, studies, access and transfer occasionally.
Context

Why the work is needed

Regulatory timelines, FDA response rates and study prices shape what a company needs before an ingredient reaches market.

75 daysminimum notice to FDA before a new dietary ingredient is marketed (21 CFR 190.6)
36.5%of 1,078 substantive FDA responses to NDI notifications, 1995 to 2020, were acknowledgments without objection
71%acknowledged among notifications filed 2010 to 2017 after a pre-NDI meeting with FDA
€105,600quoted EU price of a 90-day oral toxicity study in rats (OECD 408; range €87,200 to €161,200), quotes 2010 to 2018

21 CFR 190.6; FDA data as reported by J. Long, SupplySide Supplement Journal (December 18, 2020; June 28, 2018); Meigs et al., ALTEX 2018;35(3):275–305, Table 3.

Identity

Identity by orthogonal methods

Part 111 requires at least one appropriate test or examination to verify the identity of every dietary ingredient before use. No single method suits every material: microscopy needs intact tissue, DNA may not survive extraction, and a chromatographic fingerprint needs an authenticated reference. EUTECNIQ would combine methods whose failure modes differ.

A widely cited 2013 DNA-barcoding study of herbal products was retracted by BMC Medicine in July 2024; its figures should not be quoted. It is a reminder that a single method applied to extracts is a weak basis for an identity conclusion.

Identity methods, what each shows, its standard and its main limit
MethodWhat it showsStandard or referenceMain limit
Macroscopy and microscopyPlant part and diagnostic cell structuresCompendial monograph descriptions; voucher specimensNeeds intact or powdered tissue; not for extracts
HPTLC fingerprintPattern of constituent bands against a referenceUSP <203> HPTLC procedure for identification of articles of botanical originDepends on an authenticated reference and controlled conditions
HPLC or LC-MS fingerprint and markersMarker identity, ratios and adulterant signalsValidated method (ICH Q2(R2) principles)Markers can be added to a substitute material
DNA barcodingSpecies of origin when DNA is intactReference sequences from vouchered specimensDNA is often degraded or absent after extraction and heating

21 CFR 111.75(a)(1)(i); USP-NF <203> (2019); Retraction Note, BMC Medicine 2024, doi:10.1186/s12916-024-03504-x. Methods in depth: Botanical identity course.

Contaminants

Contaminant panels and their limits

Contaminant limits differ by product category and market, so the client's specification and destination decide which limit applies. USP <2232> limits elemental contaminants in finished dietary supplements and is not intended to set limits for dietary ingredients. ICH Q3D is written for drug products and excludes herbal products from its scope; its values are shown as a reference point.

Contaminant classes with example limits and their source
ClassExample limitSource and scope
Elements, oral PDECd 5, Pb 5, inorganic As 15, inorganic Hg 30 µg/dayICH Q3D(R2), drug products
Residual solvents, Class 1Benzene 2 ppm; carbon tetrachloride 4 ppmICH Q3C(R9)
Residual solvents, Class 2Hexane 290 ppm; methanol 3,000 ppm (Option 1)ICH Q3C(R9)
PesticidesLimits for residues of 70 pesticidesUSP <561> Articles of Botanical Origin
AflatoxinsB1 5.0 µg/kg; sum of B1, B2, G1, G2 10.0 µg/kgReg. (EU) 2023/915: Capsicum, Piper, nutmeg, ginger, turmeric
Pyrrolizidine alkaloids200 µg/kg dried herbal infusions; 400 µg/kg for chamomile, peppermint and five othersReg. (EU) 2023/915, sum of 21 PAs plus 14 co-eluting
Microbiology, dried botanicalsTAMC 105, TYMC 103 cfu/g; Salmonella and E. coli absent in 10 gUSP <2023>, Table 2
Microbiology, powdered extractsTAMC 104, TYMC 103 cfu/gUSP <2023>, Table 2

ICH Q3D(R2) (2022); ICH Q3C(R9) (2024); USP-NF <2232> (2022), <232>, <2023>; USP stakeholder-forum presentation on <561> pesticide residues (2019); Commission Regulation (EU) 2023/915, Annex I. Detail: Contaminants, Microbiology, Certificate-of-analysis science.

Methods and development Proposed

Methods, stability and development

ICH Q2(R2) and Q14 were issued by FDA as final guidances for drugs in March 2024; EUTECNIQ would apply them to supplements and ingredients as good practice. Development work would end in a transfer package that another site can run, so the client is not tied to EUTECNIQ for routine testing or production.

Proposed development services, what the client would receive, and the related page
ServiceThe client would receiveWhat it would not establishMore
Method development and validationProcedure, validation report, system-suitability criteria, transfer protocolThat the specification limits suit the productMethod development
Stability programProtocol, storage conditions, pull schedule, trend analysisA shelf life beyond the data collectedQbD and control strategy
Extraction, purification, standardizationProcess development report with mass balance and yieldCommercial-scale performance before scale-upPurification and standardization
Formulation and bioavailabilityPrototypes, physical stability, in vitro release or bioaccessibility dataSystemic bioavailability, which needs a human studyBioavailability design
Non-targeted profilingLot-to-lot or source comparison with identification confidenceThe identity of every signal, or any effectTargeted and non-targeted analysis
Technology transferTransfer dossier: process, methods, specifications, change controlPerformance at a site EUTECNIQ does not controlTransfer dossier

U.S. FDA, Q2(R2) Validation of Analytical Procedures and Q14 Analytical Procedure Development, final guidances, March 2024 (docket FDA-2022-D-1503).

Dossiers

NDIN and GRAS dossiers

About a third (36.5%) of FDA's substantive responses to new dietary ingredient notifications, 1995–2020, were acknowledgments without objection, and the rate varies widely by year. Notifications filed after a pre-NDI meeting fared better in FDA's own tracking, which is why EUTECNIQ's dossier service would start with gap analysis and a meeting request. EUTECNIQ would prepare the scientific dossier; the notifier and its counsel would sign and submit it.

FDA acknowledged 12.6% to 71% of NDI notifications without objection, depending on the yearFDA data, trade press
Share of new dietary ingredient notifications that FDA acknowledged without objection, by fiscal year, cumulatively, and for filings that followed a pre-NDI meeting; FDA data as reported by SupplySide Supplement JournalFY2017FY2017: 12.6% acknowledged without objection (FDA acknowledged 12.6% of responses without objection)12.6%FY2019FY2019: 47.5% acknowledged without objection (47.5%)47.5%FY2020FY2020: 37.2% acknowledged without objection (37.2%: 16 acknowledgments, 27 objections)37.2%FY2022FY2022: 71% acknowledged without objection (30 of 42)71.0%FY2023FY2023: 61% acknowledged without objection (27 of 44)61.0%All years 1995 to Dec 2020 (1,078 substantive responses)All years 1995 to Dec 2020 (1,078 substantive responses): 36.5% acknowledged without objection (Cumulative)36.5%Filed after a pre-NDI meeting (filings 2010 to 2017)Filed after a pre-NDI meeting (filings 2010 to 2017): 71% acknowledged without objection (Pre-NDI meetings tracked by FDA, 2009 to 2016)71.0%Percent of substantive FDA responses: acknowledged without objection (axis 0 to 100%)NDIN acknowledgment rates by year, cumulatively and after a pre-NDI meetingFY2017FY2017: 12.6%12.6%FY2019FY2019: 47.5%47.5%FY2020FY2020: 37.2%37.2%FY2022FY2022: 71%71.0%FY2023FY2023: 61%61.0%All years 1995 to Dec 2020 (1,078 substantiveresponses)All years 1995 to Dec 2020 (1,078 substantive responses): 36.5%36.5%Filed after a pre-NDI meeting (filings 2010 to 2017)Filed after a pre-NDI meeting (filings 2010 to 2017): 71%71.0%Gray track = 100% of substantive responses
Fiscal years with a verified figure only. The pre-NDI figure covers 21 meetings FDA tracked from 2009 to 2016; FDA could not confirm the total number held.FDA data obtained by J. Long, SupplySide Supplement Journal: June 28, 2018 (pre-NDI meetings); December 18, 2020 (FY2017, FY2019, FY2020, cumulative); December 12, 2023 (FY2022, FY2023).
Facts that shape an NDIN or GRAS engagement
FactValueSource
NDIN lead timeAt least 75 days before marketing21 CFR 190.6
FDA guidance on identity and safety informationFinal, issued October 19, 202691 FR 66336 (Oct 20, 2026)
FDA paperwork estimate per NDINAbout 20 hours, excluding generating safety dataFederal Register, March 28, 2018
Mandatory GRAS notificationProposed rule, August 11, 2026; comments due December 9, 202691 FR 51834; docket FDA-2025-N-3262
FDA estimate per GRAS noticeAbout 180 hours (170 to 190)91 FR 51834
GRAS and supplementsGRAS applies to food use; a supplement ingredient follows the dietary-ingredient and NDI rules instead21 CFR 190.6; 21 CFR Part 170

The GRAS rule is still a proposal. Detail: NDI notifications, GRAS and food ingredients.

Suppliers and imports

Supplier qualification and FSVP

A manufacturer may rely on a supplier's certificate only after qualifying the supplier, and importers carry their own verification duties. EUTECNIQ would build the qualification file, audit sites with or for the client, and confirm certificates by its own testing at a defined frequency.

Rules behind supplier and import work and what EUTECNIQ would deliver for each
RuleWhat it requiresProposed deliverable
21 CFR 111.75(a)(2)Qualifying a supplier before relying on its certificate of analysis for other component specificationsSupplier qualification package with confirmatory test results
21 CFR 1.511Modified FSVP for importers who, or whose customers, must set Part 111 specificationsFSVP file support for the importer
21 CFR 1.276–1.285Prior notice to FDA of imported food shipmentsDocument checklist for the importer's broker
CITES; Nagoya ProtocolPermits for listed species; provider-country access and benefit-sharing law at the point of access (the U.S. is not a Party to Nagoya)Sourcing-legality review in the supplier file

eCFR, 21 CFR 111.75 and Part 1, Subparts I and L, current to October 2026; CITES Secretariat; Convention on Biological Diversity. Buyer guide: FSVP for buyers.

Studies at partners Proposed

GLP and clinical studies at partners

EUTECNIQ would design toxicology and human studies, select and audit the partner, monitor the work and integrate the reports; it would not run GLP or clinical studies itself. 21 CFR Part 58 names food and color additives, drugs, devices and biologics, not dietary supplements, but EUTECNIQ would specify GLP for pivotal studies so one report can serve several dossiers. Human studies would run at partner CROs under IRB review and informed consent.

A 90-day rat study was quoted near €106,000; multigeneration reproduction and carcinogenicity studies about three to seven times as muchPublished price survey
Quoted prices of nine OECD toxicity studies from EU contract research organizations, 2010 to 2018, in thousands of euros; Meigs et al., ALTEX 2018, Table 3. Likely below 2026 prices.OECD 471 bacterial reverse mutation (Ames)OECD 471 bacterial reverse mutation (Ames): €3.8 thousand€3.8kOECD 487 in vitro micronucleusOECD 487 in vitro micronucleus: €8.5 thousand€8.5kOECD 473 in vitro chromosomal aberrationOECD 473 in vitro chromosomal aberration: €13.2 thousand€13.2kOECD 475 in vivo chromosomal aberrationOECD 475 in vivo chromosomal aberration: €62.5 thousand€62.5kOECD 414 prenatal developmental toxicity, ratOECD 414 prenatal developmental toxicity, rat: €77.7 thousand€77.7kOECD 408 90-day oral toxicity, ratOECD 408 90-day oral toxicity, rat: €105.6 thousand€105.6kOECD 416 two-generation reproductionOECD 416 two-generation reproduction: €328.0 thousand€328.0kOECD 443 extended one-generation reproductionOECD 443 extended one-generation reproduction: €566.0 thousand€566.0kOECD 451 carcinogenicityOECD 451 carcinogenicity: €700.0 thousand€700.0kThousand euros per study, quoted; the 90-day study ranged €87.2k to €161.2k, plus about €10kpre-test and €12k dose analyticsQuoted EU prices of nine OECD toxicity studies, thousand eurosOECD 471 bacterial reverse mutation (Ames)OECD 471 bacterial reverse mutation (Ames): €3.8k€3.8kOECD 487 in vitro micronucleusOECD 487 in vitro micronucleus: €8.5k€8.5kOECD 473 in vitro chromosomal aberrationOECD 473 in vitro chromosomal aberration: €13.2k€13.2kOECD 475 in vivo chromosomal aberrationOECD 475 in vivo chromosomal aberration: €62.5k€62.5kOECD 414 prenatal developmental toxicity, ratOECD 414 prenatal developmental toxicity, rat: €77.7k€77.7kOECD 408 90-day oral toxicity, ratOECD 408 90-day oral toxicity, rat: €105.6k€105.6kOECD 416 two-generation reproductionOECD 416 two-generation reproduction: €328.0k€328.0kOECD 443 extended one-generation reproductionOECD 443 extended one-generation reproduction: €566.0k€566.0kOECD 451 carcinogenicityOECD 451 carcinogenicity: €700.0k€700.0kQuoted EU prices, 2010 to 2018; likely below 2026prices.
Quotes from EU contract research organizations collected 2010 to 2018; they are likely below 2026 prices.Meigs L, Smirnova L, Rovida C, Leist M, Hartung T. ALTEX 2018;35(3):275–305, Table 3; doi:10.14573/altex.1807041.

21 CFR 58.1(a); 21 CFR Parts 50 and 56; ICH E6(R3). Detail: Toxicology, Clinical research.

Market access

International market access

The same ingredient can be a supplement in the United States, a traditional herbal medicinal product in the EU and a natural health product in Canada, each with different evidence rules. A market-access assessment would state the likely category, the evidence each market expects and the claims it allows, for review by local counsel.

Selected market pathways for botanical products
MarketPathwayKey condition
United StatesDietary supplement (DSHEA 1994)NDIN for ingredients not marketed before October 15, 1994; no disease claims
European UnionTraditional herbal medicinal product, Directive 2004/24/ECAt least 30 years of medicinal use, including 15 years in the EU
CanadaNatural Health Products Regulations (2004)Product license (NPN); claims supported by evidence, which may include traditional evidence
AustraliaListed complementary medicine (AUST L)Permitted ingredients and permitted indications

21 CFR 190.6; Directive 2004/24/EC; SOR/2003-196; TGA, listed complementary medicines. Detail: International market access.

Engagement Proposed

How an engagement would run

Confidentiality would come before any sample or data moves, and ownership of results would be written into the agreement before work starts. The client would be told which work goes to which partner.

Eight steps from inquiry to report, with four data rules that hold throughoutProposal
Proposed engagement model in eight steps from inquiry to report, with the confidentiality and data-ownership rules that would apply throughout1InquiryA non-confidentialdescription of the question2Mutual NDASigned before anyconfidential data or samplemoves3ScopingFeasibility, standards, andwhich work would go to anamed partner4AgreementScope, deliverables,acceptance criteria, IP anddata terms5Samples inReceipt, sample ID, chain ofcustody, storage conditions6Work to protocolApproved methods;deviations recorded; partnerwork under contract7Review and releaseTechnical review, thenquality review and signature8Report and dataReport, raw data andmethods; samples returned,kept or destroyed as agreedRules that would apply at every stepOwnershipThe client owns theproject-specific results it pays for;EUTECNIQ keeps its backgroundIP and general know-how.SegregationClient data stays in a project spacethat only the named project teamcan open.No reuse by defaultClient data never entersEUTECNIQ's proprietary dataset ormodel training without the client'swritten consent.PartnersEach partner signs equivalentconfidentiality terms, and the clientis told which partner does whichwork.Proposed engagement model in eight steps with its confidentiality and data rules1 · InquiryA non-confidential description of the question2 · Mutual NDASigned before any confidential data or samplemoves3 · ScopingFeasibility, standards, and which work would go toa named partner4 · AgreementScope, deliverables, acceptance criteria, IP anddata terms5 · Samples inReceipt, sample ID, chain of custody, storageconditions6 · Work to protocolApproved methods; deviations recorded; partnerwork under contract7 · Review and releaseTechnical review, then quality review and signature8 · Report and dataReport, raw data and methods; samples returned,kept or destroyed as agreedRules at every stepOwnershipThe client owns the project-specific results it paysfor; EUTECNIQ keeps its background IP and generalknow-how.SegregationClient data stays in a project space that only thenamed project team can open.No reuse by defaultClient data never enters EUTECNIQ's proprietarydataset or model training without the client's writtenconsent.PartnersEach partner signs equivalent confidentiality terms,and the client is told which partner does whichwork.
EUTECNIQ management proposal; ownership terms consistent with Commercialization and licensing. Every agreement would be negotiated and reviewed by counsel.
Text version of the engagement steps
  1. Inquiry: a non-confidential description of the question.
  2. Mutual NDA: signed before any confidential data or sample moves.
  3. Scoping: feasibility, applicable standards, and which work would go to a named partner.
  4. Agreement: scope, deliverables, acceptance criteria, IP and data terms.
  5. Samples in: receipt, sample identifier, chain of custody, storage conditions.
  6. Work to protocol: approved methods, recorded deviations and partner work under contract.
  7. Review and release: technical review, then quality review and signature.
  8. Report and data: report, raw data and methods; samples returned, kept or destroyed as agreed.

Throughout: the client owns the project-specific results it pays for, and EUTECNIQ keeps its background IP. Client data stays in a segregated project space and never enters EUTECNIQ's proprietary dataset or model training without written consent. Partners sign equivalent confidentiality terms.

Conflicts and confidentiality Proposed

Conflicts and confidentiality

A laboratory that also develops its own ingredients has a built-in conflict of interest. ISO/IEC 17025:2017 asks a laboratory to identify risks to its impartiality on an ongoing basis, to show how it removes or minimizes them, and to manage client information through legally enforceable commitments. EUTECNIQ would build both services and development on that frame and would plan to seek accreditation for a defined list of tests.

Two zones under one quality system: what may cross, what never crosses, and what must be declaredProposal
Proposed separation between client services and EUTECNIQ's own ingredient development: two zones under one quality system, with what may cross, what may never cross, and what must be declaredClient servicesClient samples, data and reportsClient-named project teamMethods validated for the client's questionResults released only to the clientEUTECNIQ's own developmentEUTECNIQ's own candidate ingredientsProprietary dataset and modelsOwn formulations and process know-howPatent filings and licensingFirewall: separate access rights, separaterecordsAllowedPublished methods and public data; client dataonly with written consent, as the consent definesNeverA client's unpublished composition, supplier,process or result used in EUTECNIQ's owndevelopmentDeclaredA program that competes with a client's productis disclosed before the work is accepted, or thework is declinedOne quality system: impartiality risk register and confidentiality commitments (ISO/IEC 17025:2017, clauses 4.1 and 4.2)Proposed separation between client services and EUTECNIQ's own developmentClient servicesClient samples, data and reports; Client-namedproject team; Methods validated for the client'squestion; Results released only to the clientFirewall: separate access, separate recordsEUTECNIQ's own developmentEUTECNIQ's own candidate ingredients; Proprietarydataset and models; Own formulations and processknow-how; Patent filings and licensingAllowedPublished methods and public data; client data onlywith written consent, as the consent definesNeverA client's unpublished composition, supplier,process or result used in EUTECNIQ's owndevelopmentDeclaredA program that competes with a client's product isdisclosed before the work is accepted, or the workis declinedOne quality system: ISO/IEC 17025:2017 clauses 4.1(impartiality) and 4.2 (confidentiality).
ISO/IEC 17025:2017 clauses 4.1 and 4.2 as summarized in PJLA checklist LF-56 (Rev. 1.1, December 2020); EUTECNIQ management proposal.
Proposed conflict and confidentiality rules, and the ISO/IEC 17025 clause each answers
Proposed ruleHow it would workClause it answers
Impartiality registerEach new engagement checked against EUTECNIQ's own programs; conflicts recorded with the action taken4.1.4 and 4.1.5: identify risks to impartiality; show how they are removed or minimized
Disclose or declineA competing internal program is disclosed before the client signs, or the work is declined4.1.5
Access controlClient projects open only to the named team; development staff have no default access4.2.1: management of all information through legally enforceable commitments
Consent before reuseClient data used for EUTECNIQ's dataset or models only with written consent, as the consent defines4.2.1: the customer is told in advance what would become public
Partners and personnelPartners, contractors and staff bound by the same confidentiality terms4.2.4

ISO, ISO/IEC 17025:2017 General requirements for the competence of testing and calibration laboratories (edition 3, November 2017; reviewed and confirmed 2023): requirements for "competence, impartiality, and consistent operation" of testing and calibration laboratories. Accreditation would cover only listed tests. Quality plan: Quality system.

EUTECNIQ Proposed

Where EUTECNIQ would work

Services would start with identity, contaminant, method and dossier work in the Phase I laboratory, with GLP toxicology, human studies and overflow testing at qualified partners. Consulting would cover study design, supplier audits and market access. None of this exists yet.

Related pages: Facilities and roadmap · Scientific deliverables · How EUTECNIQ differs · NDI notifications · Analytical science

Bring a question about an ingredient

An identity problem, a contaminant result, a dossier or a study to design.

Health information notice. These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice.

Read the full notice

The information is for general education only. It does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed. Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to start a development project?

Tell us about an ingredient you want to specify, verify or license. Questions? Email [email protected]